The expression of TET2 was significantly lower in the patients when compared to controls, with the low expression more pronounced in the higher risk categories (very-high- and high-risk categories combined in IPSS-R prognostic system) of MDS and in AML-MR. The gene discussed is TET2; the disease is myelodysplastic syndrome.